Efficacy and Safety of the Anti-COVID-19 Antibody SA55 for Injection in Patients With Hematological Disorders Who Are Persistently Positive for COVID-19

This study is a multicenter, randomized, single‐blind, placebo‐controlled clinical trialto evaluate the effectiveness and safety of Anti‐COVID‐19 Antibody SA55 for Injection inpatients with hematological malignancies. This study consists of two stages. In the firststage, 8 subjects aged 18‐75 were recruited for safety assessment, including themonitoring of clinical test indicators and adverse events. After confirming thepreliminary safety results of the first stage, we plan to recruit 160 COVID‐19 patientswith hematologic disorders aged 1‐75 years old and randomly divided into the SA55 groupand the placebo group with a ratio of 3:1. Basic information and laboratory tests will becollected during the whole study, and the occurrence of adverse events and SAEs of allsubjects were collected.